Beijing Biostar Pharmaceuticals Co (HKSE:02563) Construction In Progress: HK$81.13 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02563 Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
9 GF Score
Price HK$3.40
! 4 Warning Signs
View Full Analysis

What is Beijing Biostar Pharmaceuticals Co Construction In Progress?

Beijing Biostar Pharmaceuticals Co HKSE:02563 -4.23% 9 Construction In Progress is HK$81.13 Mil as of Dec. 2025. GuruFocus rates HKSE:02563 with a GF Score™ of 9/100. The stock has 4 warning signs investors should review.

Beijing Biostar Pharmaceuticals Co's quarterly construction in progress declined from Dec. 2024 (HK$104.09 Mil) to Jun. 2025 (HK$103.87 Mil) and declined from Jun. 2025 (HK$103.87 Mil) to Dec. 2025 (HK$81.13 Mil).

Beijing Biostar Pharmaceuticals Co's annual construction in progress increased from Dec. 2023 (HK$58.37 Mil) to Dec. 2024 (HK$104.09 Mil) but then declined from Dec. 2024 (HK$104.09 Mil) to Dec. 2025 (HK$81.13 Mil).

Beijing Biostar Pharmaceuticals Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Beijing Biostar Pharmaceuticals Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Biostar Pharmaceuticals Co Construction In Progress Chart

Beijing Biostar Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Construction In Progress
30.14 58.37 104.09 81.13

Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial 58.37 0.00 104.09 103.87 81.13
HKSE:02563
9GF Score
Beijing Biostar Pharmaceuticals Co Ltd HKSE:02563
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Biostar Pharmaceuticals Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$81.13 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Construction In Progress of HK$81.13 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Construction In Progress too high?
Beijing Biostar Pharmaceuticals Co's current Construction In Progress is HK$81.13 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Construction In Progress compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Construction In Progress of HK$81.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Construction In Progress is HK$81.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Construction In Progress of HK$81.13 Mil. The current Construction In Progress is HK$81.13 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Construction In Progress is HK$81.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Biostar Pharmaceuticals Co Business Description

Address 22 Ronghua Middle Road, Suite 1202, Tower B, Yicheng Fortune Center, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score

Get the complete analysis for HKSE:02563

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.40
Price